Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Safety and Efficacy of Anti-CD7 CAR-T Cell Immunotherapy in Patients With Relapse and Refractory T-cell Acute Lymphoblastic Leukemia or T Lymphoblastic Lymphoma

NCT04860817 is registered in ClinicalTrials.gov with 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China as lead sponsor.

NCT NCT04860817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Safety and Efficacy of Anti-CD7 CAR-T Cell Immunotherapy in Patients With Relapse and Refractory T-cell Acute Lymphoblastic Leukemia or T Lymphoblastic Lymphoma
Lead sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase
Phase 1
Overall status
Withdrawn
Start date
December 1, 2021
Completion date
November 1, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia, t-lymphoblastic lymphoma